Page 1

BS . DASSAULT SYSTEMES Dassault Systèmes Reports 2020 Fourth Quarter Results At the High End or Above Company Guidance VÉLIZY - VILLACOUBLAY , France February 4 , 2021 Dassault Systèmes ( Euronext Paris : # 13065 , DSY.PA ) announces IFRS unaudited financial results for the fourth quarter and year ended December 31 , 2020. The Group's Board of Directors reviewed these results on February 3 , 2021. This press release also includes financial information on a non - IFRS basis and reconciliations with IFRS figures in the Appendix to this communication . Q4 benefited from large deal activity on both a license and subscription basis FY IFRS EPS of € 1.86 and non - IFRS EPS of € 3.77 Highlights ( Unaudited , all revenue growth in constant currencies ) FY Recurring Revenue up 27 % to € 3.2 billion , 80 % of total software ( IFRS and non - IFRS ) Cash flow from operations up 5 % to € 1.24 billion for 2020 Strong MEDIDATA performance : revenues , customer growth , and backlog for 2021 DS initiates 2021 non - IFRS financial objectives : total revenue up 9 % to 10 % at constant currency and EPS of € 4.10 to € 4.15 , up 13 % to 14 % at constant currency Bernard Charlès , Dassault Systèmes ' Vice Chairman and Chief Executive Officer commented , " During this unprecedented period , we have revealed the critical importance of collaborative innovation across the three sectors we serve as a strategic partner in value creation . Through close engagement we have helped our clients to manage and reinvent their operations during the pandemic - especially for businesses in the manufacturing industries . At the same moment , our collaborative innovation platform has also enabled our clients to prepare for the future and advance their next generation portfolios for sustainable innovation . " The mission - critical nature of our platform has been most visible in Life Sciences , where a majority of the COVID - 19 clinical trials were conducted with our MEDIDATA software solutions during 2020. The health crisis has very clearly revealed the game - changing nature of our virtual twin experience , from research to patient care . The additive power of such brands as BIOVIA , SIMULIA , DELMIA and NETVIBES makes it possible to deliver healthcare industry solutions to ensure that the creation and manufacture of vaccines and therapeutics reach all of us around the globe . " As part of our purpose , we committed to maintaining our global people resources , with no outside governmental support . Moreover , we continued to invest in expanding our Research & Development teams , internally and externally , adding critical resources around our data science initiatives , as our R & D is about supporting our clients ' next generation of innovation . " Financial Summary In millions of Euros , except per share data and percentages Total Revenue Software Revenue Operating Margin EPS Q4 2020 1,219.3 1,105.3 23.2 % 0.77 Q4 2019 1,183.1 1,038.2 18.8 % 0.69 IFRS Change 3 % 6 % + 4.4pts 11 % Change in constant currencies 7 % 11 % YTD 2020 4,452.2 4,012.6 15.0 % 1.86 YTD 2019 4,018.2 3,539.4 20.2 % 2.34 IFRS Change 11 % 13 % ( 5.2 ) pts ( 20 ) % Change in constant currencies 12 % 15 %